Relapsed/Refractory Hairy Cell Leukemia
2 clinical trials · Condition
◉ Watch Relapsed/Refractory Hairy Cell Leukemia
| Record | Firm | Date |
|---|---|---|
| An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (NCT03501615) | AstraZeneca |
Track Relapsed/Refractory Hairy Cell Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.